Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00082888 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Nodal Marginal Zone Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Tipifarnib

Sponsor

National Cancer Institute (NCI)